Dianthus Therapeutics Inc
DNTH44.100USD
+0.100+0.23%
Close 01/16, 16:00（ET）Quotes delayed by 15 min
1.89BMarket Cap
LossP/E TTM
More Details of Dianthus Therapeutics Inc Company
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company engaged in designing and delivering monoclonal antibodies with improved selectivity and potency. The Company is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. It is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).
Dianthus Therapeutics Inc Info
Ticker SymbolDNTH
Company nameDianthus Therapeutics Inc
IPO dateJun 21, 2018
CEOGarcia (Marino)
Number of employees78
Security typeOrdinary Share
Fiscal year-endJun 21
Address7 Times Square
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10036
Phone19299994055
Websitehttps://dianthustx.com/
Ticker SymbolDNTH
IPO dateJun 21, 2018
CEOGarcia (Marino)
Company Executives of Dianthus Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Simrat Randhawa, M.D.
Dr. Simrat Randhawa, M.D.
Chief Medical Officer
Chief Medical Officer
4.00K
--
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ryan Savitz
Mr. Ryan Savitz
Chief Financial Officer, Chief Business Officer Treasurer
Chief Financial Officer, Chief Business Officer Treasurer
--
--
Mr. Edward Carr
Mr. Edward Carr
Chief Accounting Officer
Chief Accounting Officer
--
--
Mr. Adam M. Veness, Esq., J.D.
Mr. Adam M. Veness, Esq., J.D.
Senior Vice President, General Counsel, Company Secretary
Senior Vice President, General Counsel, Company Secretary
--
--
Mr. Steven Romano
Mr. Steven Romano
Independent Director
Independent Director
--
--
Mr. Sujay Kango
Mr. Sujay Kango
Independent Director
Independent Director
--
--
Mr. John C. King
Mr. John C. King
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Simon Read, Ph.D.
Dr. Simon Read, Ph.D.
Independent Director
Independent Director
--
--
Ms. Alison F. Lawton
Ms. Alison F. Lawton
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Simrat Randhawa, M.D.
Dr. Simrat Randhawa, M.D.
Chief Medical Officer
Chief Medical Officer
4.00K
--
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ryan Savitz
Mr. Ryan Savitz
Chief Financial Officer, Chief Business Officer Treasurer
Chief Financial Officer, Chief Business Officer Treasurer
--
--
Mr. Edward Carr
Mr. Edward Carr
Chief Accounting Officer
Chief Accounting Officer
--
--
Mr. Adam M. Veness, Esq., J.D.
Mr. Adam M. Veness, Esq., J.D.
Senior Vice President, General Counsel, Company Secretary
Senior Vice President, General Counsel, Company Secretary
--
--
Mr. Steven Romano
Mr. Steven Romano
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q3
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
396.00K
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Jan 2
Updated: Fri, Jan 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
13.73%
RA Capital Management, LP
6.69%
Wellington Management Company, LLP
6.01%
Octagon Capital Advisors LP
5.64%
Fairmount Funds Management LLC
4.98%
Other
62.95%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
13.73%
RA Capital Management, LP
6.69%
Wellington Management Company, LLP
6.01%
Octagon Capital Advisors LP
5.64%
Fairmount Funds Management LLC
4.98%
Other
62.95%
Shareholder Types
Shareholders
Proportion
Hedge Fund
37.11%
Investment Advisor
32.43%
Investment Advisor/Hedge Fund
20.75%
Venture Capital
13.11%
Corporation
3.35%
Research Firm
1.65%
Private Equity
0.29%
Pension Fund
0.08%
Bank and Trust
0.05%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
269
45.13M
105.25%
+1.42M
2025Q3
262
47.37M
104.73%
+7.65M
2025Q2
229
39.60M
125.17%
+1.05M
2025Q1
225
38.14M
115.10%
+1.17M
2024Q4
221
35.31M
117.69%
+2.28M
2024Q3
220
31.55M
110.44%
+1.66M
2024Q2
202
29.76M
95.11%
+3.64M
2024Q1
206
26.10M
70.38%
+5.44M
2023Q4
202
10.31M
84.85%
+214.29K
2023Q3
217
10.09M
29.94%
+8.27M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
5.89M
13.73%
+1.44M
+32.33%
Sep 30, 2025
RA Capital Management, LP
2.87M
6.69%
--
--
Sep 30, 2025
Wellington Management Company, LLP
2.58M
6.01%
+2.50M
+3366.88%
Sep 30, 2025
Octagon Capital Advisors LP
2.42M
5.64%
+75.00K
+3.20%
Sep 30, 2025
Fairmount Funds Management LLC
2.14M
4.98%
-1.17M
-35.38%
Nov 21, 2025
Avidity Partners Management LP
2.10M
4.91%
-1.10M
-34.33%
Nov 17, 2025
Point72 Asset Management, L.P.
2.04M
4.76%
+649.44K
+46.64%
Sep 30, 2025
TCG Crossover Management, LLC
1.68M
3.91%
+175.00K
+11.65%
Sep 30, 2025
The Vanguard Group, Inc.
1.64M
3.83%
+196.12K
+13.56%
Sep 30, 2025
Tellus Bioventures LLC
1.44M
3.35%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
1.72%
Virtus LifeSci Biotech Clinical Trials ETF
1.23%
Invesco Dorsey Wright Healthcare Momentum ETF
0.6%
ALPS Medical Breakthroughs ETF
0.47%
State Street SPDR S&P Biotech ETF
0.15%
Avantis US Small Cap Equity ETF
0.11%
iShares Micro-Cap ETF
0.11%
Direxion Daily S&P Biotech Bull 3X Shares
0.09%
Vanguard US Momentum Factor ETF
0.07%
iShares Russell 2000 Value ETF
0.04%
View more
iShares Neuroscience and Healthcare ETF
Proportion1.72%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.23%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion0.6%
ALPS Medical Breakthroughs ETF
Proportion0.47%
State Street SPDR S&P Biotech ETF
Proportion0.15%
Avantis US Small Cap Equity ETF
Proportion0.11%
iShares Micro-Cap ETF
Proportion0.11%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.09%
Vanguard US Momentum Factor ETF
Proportion0.07%
iShares Russell 2000 Value ETF
Proportion0.04%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Ex-dividend Date
Type
Ratio
Sep 11, 2023
Merger
16→1
Sep 11, 2023
Merger
16→1
Sep 11, 2023
Merger
16→1
Sep 11, 2023
Merger
16→1
Date
Ex-dividend Date
Type
Ratio
Sep 11, 2023
Merger
16→1
Sep 11, 2023
Merger
16→1
Sep 11, 2023
Merger
16→1
Sep 11, 2023
Merger
16→1
FAQs
Who are the top five shareholders of Dianthus Therapeutics Inc?
The top five shareholders of Dianthus Therapeutics Inc are:
Fidelity Management & Research Company LLC holds 5.89M shares, accounting for 13.73% of the total shares.
RA Capital Management, LP holds 2.87M shares, accounting for 6.69% of the total shares.
Wellington Management Company, LLP holds 2.58M shares, accounting for 6.01% of the total shares.
Octagon Capital Advisors LP holds 2.42M shares, accounting for 5.64% of the total shares.
Fairmount Funds Management LLC holds 2.14M shares, accounting for 4.98% of the total shares.
Fidelity Management & Research Company LLC holds 5.89M shares, accounting for 13.73% of the total shares.
RA Capital Management, LP holds 2.87M shares, accounting for 6.69% of the total shares.
Wellington Management Company, LLP holds 2.58M shares, accounting for 6.01% of the total shares.
Octagon Capital Advisors LP holds 2.42M shares, accounting for 5.64% of the total shares.
Fairmount Funds Management LLC holds 2.14M shares, accounting for 4.98% of the total shares.
What are the top three shareholder types of Dianthus Therapeutics Inc?
The top three shareholder types of Dianthus Therapeutics Inc are:
Fidelity Management & Research Company LLC
RA Capital Management, LP
Wellington Management Company, LLP
Fidelity Management & Research Company LLC
RA Capital Management, LP
Wellington Management Company, LLP
How many institutions hold shares of Dianthus Therapeutics Inc (DNTH)?
As of 2025Q4, 269 institutions hold shares of Dianthus Therapeutics Inc, with a combined market value of approximately 45.13M, accounting for 105.25% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 0.51%.
What is the biggest source of revenue for Dianthus Therapeutics Inc?
In FY2025Q3, the -- business generated the highest revenue for Dianthus Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
